Asymmetrex Suggests a Stemgene Relief from Recent Cancer Woes About...

Four months ago, alarms were set off by two reports showing that CRISPR-Cas9 gene editing of non-transformed human cells occurred with a high frequency of carcinogenic mutations in the p53 cancer...(PRWeb October 18, 2018)Read the full story at https://www.prweb.com/releases/asymmetrex_suggests_a_stemgene_relief_from_recent_cancer_woes_about_crispr_cas9_gene_editing_therapies/prweb15848432.htm
Source: PRWeb: Medical Pharmaceuticals - Category: Pharmaceuticals Source Type: news